Comparative Pharmacology
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus MECLOFENAMATE SODIUM.
FLURBIPROFEN SODIUM vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category D/X
Category C
NSAID
NSAID